Evidence map›Paper›PMID 38472443›Full record

ArticleActa neuropathologica2024

Role of GBA variants in Lewy body disease neuropathology.

Ronald L Walton, Shunsuke Koga, Alexandra I Beasley, Launia J White, Teresa Griesacker, Melissa E Murray, Koji Kasanuki, Xu Hou, Fabienne C Fiesel, Wolfdieter Springer and 20 more

Open access · greenAbstract read
In one paragraph

Article in Acta neuropathologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Classification and Genotype-Phenotype Relationships of GBA1 Variants: MDSGene Systematic Review.Movement disorders : official journal of the Movement Disorder Society · 2025
    Pooled it
  2. E326KJournal of Parkinson's disease · 2026
    Article
  3. Effect of genetic factors on [European journal of nuclear medicine and molecular imaging · 2026
    Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Pathology and genetics in a global cohort of Parkinsonian Disorders.medRxiv : the preprint server for health sciences · 2026
    Article
  9. Article
  10. Serum phosphorylated tau 217 inJournal of Parkinson's disease · 2026
    Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Targeting mitophagy in neurodegenerative diseases.Nature reviews. Drug discovery · 2025
    Review
  16. Review
  17. Review
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 4 institutions in 1 country.

Ronald L Walton *Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Shunsuke Koga *Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Alexandra I BeasleyDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Launia J WhiteDivision of Clinical Trials and Biostatistics, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, USA.
Teresa GriesackerDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Melissa E MurrayDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Koji KasanukiDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Xu HouDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Fabienne C FieselDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Wolfdieter SpringerDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Ryan J UittiDepartment of Neurology, Mayo Clinic, Jacksonville, FL, USA.
Julie A FieldsDepartment of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, USA.
Hugo BothaDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Vijay K RamananDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Kejal KantarciDepartment of Neuroradiology, Mayo Clinic, Rochester, MN, USA.
Val J LoweDepartment of Nuclear Medicine, Mayo Clinic, Rochester, MN, USA.
Clifford R JackDepartment of Neuroradiology, Mayo Clinic, Rochester, MN, USA.
Nilufer Ertekin-TanerDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Rodolfo SavicaDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Jonathan Graff-RadfordDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Ronald C PetersenDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Joseph E ParisiLaboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
R Ross ReichardLaboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Neill R Graff-RadfordDepartment of Neurology, Mayo Clinic, Jacksonville, FL, USA.
Tanis J FermanDepartment of Psychiatry and Psychology, Mayo Clinic, Jacksonville, FL, USA.
Bradley F BoeveDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Zbigniew K WszolekDepartment of Neurology, Mayo Clinic, Jacksonville, FL, USA.
Dennis W DicksonDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Owen A Ross *Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Michael G HeckmanDivision of Clinical Trials and Biostatistics, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, USA. heckman.michael@mayo.edu.ORCID 0000-0003-3770-9331
Mayo Clinic in Florida · USMayo Clinic in Arizona · USWinnMed · USMayo Clinic · US

Funding

Technology and Remote Assessment CoreU19AG063911 · NIA · MAYO CLINIC ROCHESTER · PI KEJAL KANTARCI · 2019 to 2026
$120.9M
Vascular Structure and Function in Cognitive AgingP01AG003949 · NIA · YESHIVA UNIVERSITY · PI Richard B. LIPTON · 1985 to 2026
$73.9M
Peripheral and Central Biomarkers of Alzheimer's Disease in Diverse CohortsU19AG074879 · NIA · MAYO CLINIC JACKSONVILLE · PI Minerva Maria Carrasquillo, NILUFER ERTEKIN-TANER · 2023 to 2026
$42.0M
Project: Predicting PhenoconversionU19AG071754 · NIA · WASHINGTON UNIVERSITY · PI Bradley F Boeve, Yo-El S Ju · 2021 to 2026
$41.2M
THE PGRN/TDP-43 AXIS IN ALZHEIMER?S DISEASE AND NEURODEGENERATIONP50AG016574 · NIA · MAYO CLINIC ROCHESTER · PI PETERSEN, RONALD C · 1999 to 2018
$36.9M
Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI KEJAL KANTARCI · 2019 to 2026
$33.5M
Longitudinal Imaging Biomarkers of Prodromal DLBU01NS100620 · NINDS · MAYO CLINIC ROCHESTER · PI Bradley F Boeve, KEJAL KANTARCI · 2017 to 2026
$19.2M
Utilization of proteomics and lipidomics to identify modifiers of LBDU54NS110435 · NINDS · MAYO CLINIC JACKSONVILLE · PI MCLEAN, PAMELA J · 2019 to 2023
$14.5M
Neuropathology CoreP50NS072187 · NINDS · MAYO CLINIC JACKSONVILLE · PI DICKSON, DENNIS WILLIAM · 2010 to 2017
$8.7M
Project 2: Identifying genes and Pathways that impact Tau Toxicity in FTDU54NS100693 · NINDS · MAYO CLINIC JACKSONVILLE · PI DICKSON, DENNIS WILLIAM · 2016 to 2020
$6.2M
Impact of coding and non-coding variation in progressive supranuclear palsyUG3NS104095 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DICKSON, DENNIS WILLIAM, GESCHWIND, DANIEL H · 2017 to 2019
$3.6M
Mitochondrial Sirtuin 3 in Parkinson's diseaseR01NS110085 · NINDS · MAYO CLINIC JACKSONVILLE · PI MCLEAN, PAMELA J, SPRINGER, WOLFDIETER · 2019 to 2023
$2.5M
NIA NIH HHS P01 AG003949NIA NIH HHS P30 AG062677NIA NIH HHS P50 AG016574NIA NIH HHS R56 AG062556NIA NIH HHS U19 AG063911NIA NIH HHS U19 AG071754NIA NIH HHS U19 AG074879NIH HHS P50-NS072187NINDS NIH HHS P50 NS072187NINDS NIH HHS R01 NS078086NINDS NIH HHS R01 NS085070NINDS NIH HHS R01 NS110085NINDS NIH HHS U01 NS100620NINDS NIH HHS U54 NS100693NINDS NIH HHS U54 NS110435NINDS NIH HHS UG3 NS104095
6 · The paper itself

Abstract

Rare and common GBA variants are risk factors for both Parkinson's disease (PD) and dementia with Lewy bodies (DLB). However, the degree to which GBA variants are associated with neuropathological features in Lewy body disease (LBD) is unknown. Herein, we assessed 943 LBD cases and examined associations of 15 different neuropathological outcomes with common and rare GBA variants. Neuropathological outcomes included LBD subtype, presence of a high likelihood of clinical DLB (per consensus guidelines), LB counts in five cortical regions, tyrosine hydroxylase immunoreactivity in the dorsolateral and ventromedial putamen, ventrolateral substantia nigra neuronal loss, Braak neurofibrillary tangle (NFT) stage, Thal amyloid phase, phospho-ubiquitin (pS65-Ub) level, TDP-43 pathology, and vascular disease. Sequencing of GBA exons revealed a total of 42 different variants (4 common [MAF > 0.5%], 38 rare [MAF < 0.5%]) in our series, and 165 cases (17.5%) had a copy of the minor allele for ≥ 1 variant. In analysis of common variants, p.L483P was associated with a lower Braak NFT stage (OR = 0.10, P < 0.001). In gene-burden analysis, presence of the minor allele for any GBA variant was associated with increased odds of a high likelihood of DLB (OR = 2.00, P < 0.001), a lower Braak NFT stage (OR = 0.48, P < 0.001), a lower Thal amyloid phase (OR = 0.55, P < 0.001), and a lower pS65-Ub level (β: -0.37, P < 0.001). Subgroup analysis revealed that GBA variants were most common in LBD cases with a combination of transitional/diffuse LBD and Braak NFT stage 0-II or Thal amyloid phase 0-1, and correspondingly that the aforementioned associations of GBA gene-burden with a decreased Braak NFT stage and Thal amyloid phase were observed only in transitional or diffuse LBD cases. Our results indicate that in LBD, GBA variants occur most frequently in cases with greater LB pathology and low AD pathology, further informing disease-risk associations of GBA in PD, PD dementia, and DLB.

Indexed as

Alzheimer DiseaseLewy Body DiseaseParkinson DiseaseHumansNeurofibrillary TanglesSubstantia NigraGBAGeneticsLewy body diseaseNeuropathology

Identifiers

PMID38472443
PMCPMC11049671
OpenAlexW4392679099

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.